AGP Executive Report
Last update: 6 hours agoPrivate Markets Pressure: Partners Group’s stock took a hit after it halted withdrawals on an $8.6bn fund, with investors pushing for cash back as private-market returns look less “meteoric.” Biotech Deal: Roche is paying $700m upfront to join Nurix’s late-phase BTK degrader programme (bexobrutideg), aiming at CLL/SLL and setting up a phase 3 showdown with Lilly’s Jaypirca. Neuroscience Breakthrough: Researchers at the University of Geneva and partners including ETH Zurich and EPFL improved non-invasive “temporal interference” brain stimulation to better reach deeper targets for disorders like Parkinson’s and depression. Industrial Warning: ABB’s CEO warned Europe could face mass unemployment unless the EU cuts regulation and speeds reforms. Energy Politics: A Swiss poll finds growing support for nuclear power, as parliament debates future energy policy amid supply-security fears. Public Safety: ETH Zurich successfully disposed of a hazardous chlorine trifluoride cylinder after evacuating residents for several hours. Swiss Tech & Finance: BrickMark X and financial.com plan a hybrid tokenized-RWA platform for regulated trading across Europe and the UAE. Health Research: ETH Zurich reported a compound that slows Alzheimer’s progression in mice, pointing to a possible new drug target.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
